Quarterly report pursuant to Section 13 or 15(d)

Goodwill and In-Process R&D (Details)

v3.19.3
Goodwill and In-Process R&D (Details) - USD ($)
9 Months Ended
Sep. 30, 2019
Dec. 31, 2018
Business Acquisition [Line Items]    
Goodwill $ 1,452,338 $ 2,189,338
Goodwill gross 2,200,000  
Impairment loss 737,000  
Pelican Therapeutics, Inc. [Member]    
Business Acquisition [Line Items]    
Goodwill 2,200,000  
In-process R&D $ 5,900,000